

Substitute for form 1449A/B/PTO				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/523328
				Filing Date	February 1, 2005
				First Named Inventor	Jun Kwei
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	WYTH-P01-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,776,717	07-07-1998	Cao, Z.	
	AB	5,837,514	11-17-1998	Cao, Z.	
	AC	6,294,348-B1	09-25-2001	Goeddel, D.V. and Rothe, M.	
	AD	6,365,366-B1	04-02-2002	Cao, Z.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	01/68908-A2	09-20-2001	Tularik Inc.	
	BB	2004/012673-A2	02-12-2004	Wyeth	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Code of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \* Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Balkwill, F., et al., "TNF is here to stay!", Immunology Today, 21(10) (October 2000).			
	CB	Baud, V. and Karin, M., "Signal transduction by tumor necrosis factor and its relatives," Trends in Cell Biology, 11(9):372-377 (2001).			
	CC	Bell, S. and Kamm, M.A., "Antibodies to tumour necrosis factor $\alpha$ as treatment for Crohn's disease," The Lancet (Commentary), 355:858-860 (2000).			
	CD	Clark, G.J., et al., "p120 GAP Modulates Ras Activation of Jun Kinases and Transformation," The Journal of Biological Chemistry, 272(3):1677-1681 (1997).			
	CE	Fitzgerald, K.A., et al., "IKK $\epsilon$ and TBK1 are essential components of the IRF3 signaling pathway," Nature Immunology, 4(5):491-496 (2003).			
	CF	Friedman, E., "The Role of ras GTPase Activating Protein in Human Tumorigenesis," Pathobiology, 63:348-350 (1995).			
	CG	Galon, J., et al., "TNFRSF1A mutations and autoinflammatory syndromes," Current Opinion in Immunology, 12:479-486 (2000).			
	CH	Gambin, S.J. and Smerdon, S.J., "GTPase-activating proteins and their complexes," Current Opinion in Structural Biology, 8:195-201 (1998).			
	CI	Heyninck, K. and Beyaert, R., "Cross-talk between NF- $\kappa$ B-Activating and Apoptosis-Inducing Proteins of the TNF-Receptor Complex," Molecular Cell Biology Research Communications, 4:259-265 (2001).			
	CJ	Idriss, H.T. and Naismith, J.H., "TNF $\alpha$ and the TNF Receptor Superfamily: Structure-Function Relationship(s)," Microscopy Research and Technique, 50:184-195 (2000).			
	CK	Jones, R.E. and Moreland, L.W., "Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis," Rheumatic Diseases (Bulletin), 48(3):1-4 (1999).			
	CL	Kishore, N., et al., "IKK-1 and TBK-1 are Enzymatically Distinct from the Homologous Enzyme IKK-2," The Journal of Biological Chemistry, 277(16):13840-13847 (2002).			

Examiner Signature	/Gregory Emch/	Date Considered	06/30/2008
--------------------	----------------	-----------------	------------

9732959.1  
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

Substitute for form 1449A/B/PTO  <h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 5px 0;">(Use as many sheets as necessary)</p>				<b>Complete If Known</b>	
		Application Number	10/523328		
		Filing Date	February 1, 2005		
		First Named Inventor	Jun Kuai		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet		2	of	2	Attorney Docket Number
		WYTH-P01-001			

	CM	Kuai, J. et al., "NAK is Recruited to the TNFR1 Complex in a TNF $\alpha$ -dependent Manner and Mediates the Production of RANTES", The Journal of Biological Chemistry, 279(51):53286-53271 (2004)	
	CN	MacEwan, D.J., "TNF receptor subtype signalling: Differences and cellular consequences," Cellular Signalling, 14:477-492 (2002).	
	CO	Mak, T.W. and Yeh, W-C., "Signaling for survival and apoptosis in the immune system," Arthritis Research. 09 May 2002, Vol. 4 (Suppl. 3), S243-S252 (online pages 1-19).	
	CP	McFarlane, S.M., et al., "Differential activation of nuclear factor- $\kappa$ B by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly," FEBS Letters, 515:119-126 (2002).	
	CQ	Natoli, G., et al., "Apoptotic, Non-apoptotic, and Anti-apoptotic Pathways of Tumor Necrosis Factor Signalling," Biochemical Pharmacology, 56:915-920 (1998).	
	CR	Pomerantz, J.L. and Baltimore, D., "NF $\kappa$ B activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase," The EMBO Journal, 18(23):6694-6704 (1999).	
	CS	Wen, L-P., et al., "Proteolytic cleavage of Ras GTPase-activating protein during apoptosis," Cell Death and Differentiation, 5:729-734 (1998).	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Gregory Emch/	Date Considered	06/30/2008
--------------------	----------------	-----------------	------------

9732959\_1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./